Prosight Management’s AN2 Therapeutics ANTX Stock Holding History

Prosight Management’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.3M	Sell	474,638 -41,116	-8%	-$177K	0.4%	29
2026 Q1	$1.76M	Buy	+515,754	New	+$1.06M	0.29%	35

Other funds holding ANTX

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Prosight Management's ANTX Position: Q2 2026 in Review

Prosight Management reduced its AN2 Therapeutics (ANTX) stake by 8% in Q2 2026, selling an estimated $177K and leaving 474,638 shares worth $2.3M. The position accounts for 0.4% of the portfolio, ranked #29.

Prosight Management first reported a position in ANTX in Q1 2026 and has held it in 2 quarters since. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

Prosight Management held 474,638 shares of AN2 Therapeutics worth $2.3M as of Q2 2026.
Prosight Management sold 41,116 AN2 Therapeutics shares in Q2 2026, an estimated $177K.
AN2 Therapeutics made up 0.4% of Prosight Management's portfolio in Q2 2026, its #29 holding.
Prosight Management first reported a position in AN2 Therapeutics in Q1 2026 and has held it in 2 quarters since.
66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.